Our research aims to elucidate the underlying mechanism of AURKA-mediated B7-H3 upregulation and explore the potential of combining the AURKA inhibitor alisertib with B7-H3–specific blocking mAbs as a promising therapeutic strategy for GBM treatment. Here, CD276 is linked to glioblastoma.